Wesbanco Bank Inc. Makes New $907,000 Investment in Haemonetics Corporation $HAE

Wesbanco Bank Inc. acquired a new stake in Haemonetics Corporation (NYSE:HAE) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,100 shares of the medical instruments supplier’s stock, valued at approximately $907,000.

A number of other institutional investors and hedge funds have also made changes to their positions in HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Haemonetics by 3.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after buying an additional 971 shares during the period. Caxton Associates LLP acquired a new stake in Haemonetics in the 1st quarter valued at $216,000. United Services Automobile Association purchased a new stake in Haemonetics in the 1st quarter worth $212,000. Empowered Funds LLC increased its holdings in Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after acquiring an additional 9,051 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Bank of America raised shares of Haemonetics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $72.00 to $80.00 in a report on Friday, May 22nd. Barrington Research reduced their price target on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Robert W. Baird set a $67.00 price target on shares of Haemonetics in a research report on Friday, May 8th. Weiss Ratings raised shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday. Finally, Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus price target of $78.33.

Haemonetics Stock Up 0.1%

NYSE HAE opened at $77.34 on Monday. The business’s fifty day simple moving average is $65.41 and its 200-day simple moving average is $66.76. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The firm has a market cap of $3.51 billion, a PE ratio of 38.29, a P/E/G ratio of 1.56 and a beta of 0.55. Haemonetics Corporation has a 52 week low of $47.31 and a 52 week high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. During the same quarter in the prior year, the firm posted $1.24 earnings per share. Haemonetics’s quarterly revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, equities analysts anticipate that Haemonetics Corporation will post 5.22 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.